Pharma BD Deal Intelligence
BMS's $14B bet on KarXT—a first-in-class muscarinic agonist for schizophrenia—paid off at the gate: the FDA approved it as Cobenfy on Sept 26, 2024, the first new schizophrenia mechanism in decades and the cornerstone of a post-Opdivo neuroscience franchise. The broader expansion thesis the deal was priced on is now more contested: the Phase 3 ARISE trial in adjunctive schizophrenia missed its primary endpoint in April 2025 (2.0-pt PANSS reduction vs placebo, p=0.11), and the franchise's value increasingly hinges on label expansion into Alzheimer's disease psychosis and other neuropsychiatric indications still in development.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
BMS acquired Karuna Therapeutics for $14B for schizophrenia treatment KarXT.
Karuna Therapeutics surges 47% after Bristol Myers Squibb announces $14 billion deal. The centerpiece of the acquisition is KarXT, an antipsychotic with a…
ARISE Phase 3 (adjunctive Cobenfy to atypical antipsychotics) missed primary endpoint: 2.0-pt PANSS reduction vs placebo, p=0.11 (not significant). Tempers the…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
BMS acquired Karuna Therapeutics for $14B for schizophrenia treatment KarXT.
KarXT (xanomeline/trospium) is in Phase 3 ADEPT-2 for Alzheimer's disease psychosis, positioning as the first muscarinic M1/M4 agonist in this indication. The field has no MOA-matched competitor and is segmented as follows. 5-HT2A inverse agonists: Acadia's pimavanserin (Nuplazid) is FDA approved for Parkinson's disease psychosis and failed its HARMONY AD psychosis trial in 2021; a targeted hallucinations subpopulation resubmission remains under discussion with FDA. Atypical antipsychotics (off-label, boxed warning for elderly dementia patients increasing mortality): risperidone (Risperdal/generics), quetiapine (Seroquel/generics), aripiprazole (Abilify/generics), olanzapine (Zyprexa/generics) remain the de-facto standard despite the FDA boxed warning; Otsuka/Lundbeck's brexpiprazole (Rexulti) received FDA approval May 2023 for agitation associated with AD dementia, adjacent to psychosis. Emerging: Bioxcel's BXCL501 (dexmedetomidine sublingual film, TRANQUILITY Phase 3 in AD agitation), BioVie's bezisterim, and anti-amyloid therapies (Leqembi, Kisunla) that may reduce NPS incidence upstream. Rexulti's $1.3B FY2023 sales (Otsuka disclosure) and its approved agitation indication represent the primary franchise threat in the broader AD-NPS competitive space KarXT must split. Source: FDA Rexulti approval letter for Alzheimer's agitation.
KarXT (xanomeline/trospium), rebranded Cobenfy, is in Phase 3 ADEPT program for Alzheimer's cognitive impairment and represents the first muscarinic M1/M4 agonist pursuing cognition in AD. The competitive landscape spans four MOA classes. Cholinesterase inhibitors (standard of care, all generic): donepezil (Aricept), rivastigmine (Exelon patch), and galantamine (Razadyne) dominate symptomatic mild-moderate AD treatment but have plateaued commercially. NMDA receptor antagonist: memantine (Namenda/Namenda XR, generic) used in moderate-severe AD, often combined with donepezil (Namzaric). Anti-amyloid monoclonal antibodies (disease-modifying, not pure cognition): Eisai/Biogen's lecanemab (Leqembi, FDA approved 2023) and Eli Lilly's donanemab (Kisunla, FDA approved 2024) slow clinical decline in early AD. Competing procognitive mechanisms in development include AbbVie/Cerevel's emraclidine (M4 PAM, Phase 2 AD cognition readout expected), Neumora's navacaprant (kappa opioid, discontinued 2024), and Athira's fosgonimeton (HGF positive modulator, Phase 3 failed 2023). KarXT's differentiated muscarinic mechanism offers class-first positioning if ADEPT succeeds, though Leqembi and Kisunla dominate disease-modification mindshare. Source: FDA Leqembi approval letter.
Cobenfy (xanomeline/trospium), FDA approved September 2024, is the first muscarinic M1/M4 agonist with peripheral anticholinergic for schizophrenia and breaks a 70-year D2-blockade paradigm. The competitive landscape groups into four MOA classes. Second-generation atypical antipsychotics (D2/5-HT2A): olanzapine (Zyprexa/generics), risperidone (Risperdal/generics, Perseris monthly), aripiprazole (Abilify/generics, Abilify Maintena, Aristada), paliperidone (Invega, Invega Sustenna/Trinza/Hafyera LAI franchise J&J FY2023 ~$4.1B per 10-K), and lurasidone (Latuda, generic) form the volume core. Third-generation partial agonists: cariprazine (Vraylar, AbbVie) and brexpiprazole (Rexulti, Otsuka/Lundbeck) with improved metabolic profiles. Novel non-D2 mechanisms: lumateperone (Caplyta, Intra-Cellular acquired by J&J 2025) with presynaptic serotonin/postsynaptic D2 modulation, FY2023 sales $462M per Intra-Cellular 10-K; AbbVie/Cerevel's emraclidine (M4 PAM) Phase 2 EMPOWER trials failed November 2024, reducing near-term muscarinic competition. First-generation typical antipsychotics (D2 only): haloperidol, chlorpromazine (generic, residual use). Cobenfy's weight-neutral, non-EPS profile positions it for treatment-refractory and metabolically fragile patients; Caplyta and LAI paliperidone are the primary franchise threats. Source: FDA Cobenfy approval letter.
KarXT (xanomeline/trospium) is in Phase 3 ARISE program for bipolar I mania, positioning as the first muscarinic M1/M4 agonist in this indication; the current bipolar I market is dominated by four MOA-differentiated classes, with no approved muscarinic competitor. Second-generation atypical antipsychotics (D2/5-HT2A antagonists and partial agonists): quetiapine (Seroquel/generics), olanzapine (Zyprexa/generics), risperidone (Risperdal/generics), aripiprazole (Abilify/generics, including once-monthly Abilify Maintena LAI), and lurasidone (Latuda, generic 2023) are the high-volume acute and maintenance mainstays; newer agents include cariprazine (Vraylar, AbbVie), approved for mania, mixed episodes, and bipolar depression with FY2023 net revenue of approximately $2.8B per AbbVie Form 10-K, and lumateperone (Caplyta, Intra-Cellular/J&J) approved 2021 for bipolar depression. Mood stabilizers (historical first-line): lithium (generic), valproate/divalproex (Depakote/generics), lamotrigine (Lamictal/generics, maintenance monotherapy). Long-acting injectables for adherence-challenged patients: Abilify Maintena, Invega Sustenna/Trinza (paliperidone), Aristada (aripiprazole lauroxil). Legacy first-generation antipsychotics: haloperidol (generic) for acute mania in hospital settings. Vraylar and Caplyta represent the principal branded franchise threat; KarXT's weight-neutral, non-D2 mechanism and absent EPS/akathisia profile are the primary differentiation levers if ARISE reads positive. Source: FDA Vraylar approval supplement label for bipolar I.
BMS announces $14B acquisition of Karuna to strengthen neuroscience with first-in-class muscarinic agonist.
KarXT shows 8.4-point PANSS reduction vs placebo at week 5; both pivotal trials meet primary endpoint.
BMS acquires Karuna at $330/share for $14B ($12.7B net of cash), adding KarXT schizophrenia asset.
FDA approves Cobenfy (xanomeline-trospium), first novel schizophrenia mechanism in decades.
Registrational trials ongoing for adjunctive schizophrenia, Alzheimer psychosis, Bipolar I.
Cobenfy approval validates $14B bet. First new schizophrenia mechanism in 30+ years. Multiple expansions in trials.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Karuna Therapeutics (this deal) | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
| Bristol-Myers Squibb Company / Turning Point Therapeutics Inc. | 2022 | $4.1B | 70 |
← Browse all deals · How we score deals
More: 2023 deals · Bristol-Myers Squibb Company deals · Neurology deals